MX2015015667A - Composicion que comprende un complejo de (+)-catequina y aminoacido para el tratamiento y prevencion de cancer. - Google Patents

Composicion que comprende un complejo de (+)-catequina y aminoacido para el tratamiento y prevencion de cancer.

Info

Publication number
MX2015015667A
MX2015015667A MX2015015667A MX2015015667A MX2015015667A MX 2015015667 A MX2015015667 A MX 2015015667A MX 2015015667 A MX2015015667 A MX 2015015667A MX 2015015667 A MX2015015667 A MX 2015015667A MX 2015015667 A MX2015015667 A MX 2015015667A
Authority
MX
Mexico
Prior art keywords
amino acid
catechin
complex
composition
cancer
Prior art date
Application number
MX2015015667A
Other languages
English (en)
Inventor
Paul Niebes
Bronislav Henric May
Saïd Rachidi
Julien Estager
Bruno Schoentjes
Original Assignee
Valore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valore filed Critical Valore
Publication of MX2015015667A publication Critical patent/MX2015015667A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

La invención se refiere a una composición terapéutica para la administración oral que comprende un compuesto de (+)-catequina monomérica y al menos un aminoácido básico, la composición que se caracteriza en que se usa en la forma de un complejo de (+)-catequina y al menos un aminoácido básico o al menos un derivado o precursor de un aminoácido básico para el tratamiento curativo y/o preventivo de cáncer, el complejo que tiene una relación de equivalencia molar de la (+)-catequina monomérica a la al menos un aminoácido básico o el al menos un derivado de aminoácido básico de entre 1:1 y 1:2.5.
MX2015015667A 2013-05-17 2014-05-13 Composicion que comprende un complejo de (+)-catequina y aminoacido para el tratamiento y prevencion de cancer. MX2015015667A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE20130350A BE1023772B9 (fr) 2013-05-17 2013-05-17 Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer
PCT/EP2014/059780 WO2014184197A1 (fr) 2013-05-17 2014-05-13 Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer

Publications (1)

Publication Number Publication Date
MX2015015667A true MX2015015667A (es) 2016-07-20

Family

ID=48951281

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015667A MX2015015667A (es) 2013-05-17 2014-05-13 Composicion que comprende un complejo de (+)-catequina y aminoacido para el tratamiento y prevencion de cancer.

Country Status (12)

Country Link
US (2) US9844595B2 (es)
EP (2) EP2996688A1 (es)
JP (2) JP2016518422A (es)
CN (1) CN105392479A (es)
AU (1) AU2014267398B2 (es)
BE (1) BE1023772B9 (es)
BR (1) BR112015028661A2 (es)
CA (1) CA2912128A1 (es)
ES (1) ES2730947T3 (es)
MX (1) MX2015015667A (es)
SG (1) SG11201509433RA (es)
WO (2) WO2014184197A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1023772B9 (fr) * 2013-05-17 2017-08-02 Valore Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer
BE1022579A9 (fr) * 2014-11-10 2016-10-06 Valore Composition antimétastatique comprenant au moins un composé de type flavanol
US10617705B1 (en) 2019-01-24 2020-04-14 Alps Pharmaceutical Ind. Co., Ltd. Isoquercitrin compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5616412A (en) * 1979-07-18 1981-02-17 Kanebo Ltd Carcinostatic agent
US4285964A (en) * 1979-08-30 1981-08-25 Continental Pharma Salts of (+)-catechine, their preparation and use, and compositions containing these salts
CH665634A5 (en) * 1985-08-30 1988-05-31 Joseph Dr Kovacs Stable soluble catechin complexes - with a double salt of L-lysine, for liver protection and digestive ulcers
GB2306321A (en) 1995-10-24 1997-05-07 Anne Child The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders
US6939860B2 (en) 2002-01-08 2005-09-06 Matthias Rath Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
CA2471932A1 (en) * 2002-01-11 2003-07-17 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
WO2007137602A1 (en) * 2006-05-29 2007-12-06 Patent Engineering Trust Reg. Method of producing a liquid oral or otherwise applicable composition for administration to human beings and animals, liquid oral or otherwise applicable composition and its use of the composition for the manufacture of a product for functional nutrition
CN1943572A (zh) * 2006-08-21 2007-04-11 浙江大学 一种具有防晒作用的口服天然植物配方
US9211298B2 (en) * 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
BE1023772B9 (fr) * 2013-05-17 2017-08-02 Valore Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer

Also Published As

Publication number Publication date
AU2014267398A1 (en) 2015-11-19
CN105392479A (zh) 2016-03-09
BR112015028661A2 (pt) 2017-07-25
JP2016518422A (ja) 2016-06-23
AU2014267398B2 (en) 2019-02-21
US20160089358A1 (en) 2016-03-31
EP2996686B1 (fr) 2019-04-03
JP2016518423A (ja) 2016-06-23
EP2996686A1 (fr) 2016-03-23
CA2912128A1 (fr) 2014-11-20
WO2014184197A1 (fr) 2014-11-20
EP2996688A1 (fr) 2016-03-23
WO2014184198A1 (fr) 2014-11-20
US9844595B2 (en) 2017-12-19
BE1023772B1 (fr) 2017-07-17
US20160095923A1 (en) 2016-04-07
BE1023772B9 (fr) 2017-08-02
ES2730947T3 (es) 2019-11-13
SG11201509433RA (en) 2015-12-30

Similar Documents

Publication Publication Date Title
WO2015095811A3 (en) Combination therapy with neoantigen vaccine
MX368703B (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
PH12016502355A1 (en) Pharmaceutical composition
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
MX2018003975A (es) Combinacion de glicosaminoglicanos y un agente antacido y sus composiciones.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
PH12016502352A1 (en) Pharmaceutical composition
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
MX2015004362A (es) Derivados de ketamina.
PH12016502353A1 (en) Pharmaceutical composition
MX2018001756A (es) Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
PH12015501783B1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
MX362879B (es) Usos novedosos.
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
BR112015029468A2 (pt) sistema de dosagem não alimentar oralmente administrável; composição oralmente administrável; método para suplementar a nutrição de ferro em um indivíduo humano com necessidade do mesmo; método para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2015015667A (es) Composicion que comprende un complejo de (+)-catequina y aminoacido para el tratamiento y prevencion de cancer.
MX2016004847A (es) Derivados de piperazina y su uso como medicamento.
MD4615C1 (ro) Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine
MX2019012522A (es) Compuestos y metodos terapeuticos.
MX2017004723A (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
MX2015012771A (es) Procedimiento de tratamiento de la deficiencia de vitamina b12.
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.